Cornea : The Journal of Cornea and External Diseases’ Post

ICYMI: Cornea Update: Stability and Sterility of Extemporaneously Prepared Nonpreserved Cefazolin, Ceftazidime, Vancomycin, Amphotericin B, and Methylprednisolone Eye Drops: Purpose: To determine in-use stability and sterility of fortified cefazolin, ceftazidime, vancomycin, amphotericin B, and methylprednisolone eye drops in a simulated inpatient setting with and without a mobile refrigerated container (MR). Methods: Each drug was prepared and divided into 4 groups: 1) simulated patient use with the MR group: stored at 4°C and kept in the MR during drug administration, 2) simulated patient use without the MR (NoMR) group: stored at 4°C and no MR, 3) refrigerated control group: stored at 4°C, and 4) room temperature control group: stored at room temperature. Stability and sterility data were evaluated at days 0, 4, 7, 14, 21, and 28. Linear mixed-effects model and survival analysis were performed. Results: Median time to 10% loss of concentration for in-use medications (MR/NoMR groups) was >28/27.9, 22.2/22.2, 19.4/19.4, 10.18/28/>28 days for cefazolin, ceftazidime, vancomycin, amphotericin B, and methylprednisolone, respectively. There was no significant difference in the predicted concentration loss per day among all groups for vancomycin and methylprednisolone (all P > 0.05). For the other study medications, all room temperature control groups, the cefazolin NoMR group, and the ceftazidime NoMR group had significantly greater predicted concentration loss per day compared with the refrigerated control groups (all P ≤ 0.02). Culture results were negative for all drugs throughout the study. Conclusions: The NoMR group showed that the drug significantly degraded rapidly for cefazolin, ceftazidime, and amphotericin B. Implementation of MR could decrease the predicted loss of concentration per day for cefazolin and ceftazidime. In vitro antimicrobial activity and sterility were retained for 28 days. http://dlvr.it/T15bFs #Cornea #MostPopularArticles #Ophthalmology

Cornea Update: Stability and Sterility of Extemporaneously Prepared Nonpreserved Cefazolin, Ceftazidime, Vancomycin, Amphotericin B, and Methylprednisolone Eye Drops: Purpose: To determine in-use stability and sterility of fortified cefazolin, ceftazidime, vancomycin, amphotericin B, and methylprednisolone eye drops in a simulated inpatient setting with and without a mobile refrigerated container (MR). Methods: Each drug was prepared and divided into 4 groups: 1) simulated patient use with the MR group: stored at 4°C and kept in the MR during drug administration, 2) simulated patient use without the MR (NoMR) group: stored at 4°C and no MR, 3) refrigerated control group: stored at 4°C, and 4) room temperature control group: stored at room temperature. Stability and sterility data were evaluated at days 0, 4, 7, 14, 21, and 28. Linear mixed-effects model and survival analysis were performed. Results: Median time to 10% loss of concentration for in-use medications (MR/NoMR groups) was >28/27.9, 22.2/22.2, 19.4/19.4, 10.18/28/>28 days for cefazolin, ceftazidime, vancomycin, amphotericin B, and methylprednisolone, respectively. There was no significant difference in the predicted concentration loss per day among all groups for vancomycin and methylprednisolone (all P > 0.05). For the other study medications, all room temperature control groups, the cefazolin NoMR group, and the ceftazidime NoMR group had significantly greater predicted concentration loss per day compared with the refrigerated control groups (all P ≤ 0.02). Culture results were negative for all drugs throughout the study. Conclusions: The NoMR group showed that the drug significantly degraded rapidly for cefazolin, ceftazidime, and amphotericin B. Implementation of MR could decrease the predicted loss of concentration per day for cefazolin and ceftazidime. In vitro antimicrobial activity and sterility were retained for 28 days. http://dlvr.it/T0cBd9 #Cornea #MostPopularArticles #Ophthalmology

As per DelveInsight Business Research LLP, the overall prevalent population of Diabetic Foot Ulcers in the 7MM was reported as 6.2 million in 2022. The Diabetic Foot Ulcers market is undergoing dynamic evolution, driven by the rise in the number of cases, advancement in treatment modalities, increased awareness, and the launch of new therapies in the market. Prominent pharma and biotech companies such as Anterogen, Vitruvian Medical Devices, Oneness Biotech Co Ltd, Energenesis Biomedical, Tissue & Cell Technologies, PolarityTE, TechnoPhage, SA, and others, are actively working on innovative drugs for Diabetic Foot Ulcers. These novel therapies are anticipated to enter the Diabetic Foot Ulcers market in the near future and are expected to change the treatment dynamics and market outlook. Get a more detailed assessment, at: https://lnkd.in/dFbtihNz #lifesciences #pharmaceuticals #marketresearch #marketanalysis #healthcare #markettrends #health #medical #clinicaltrials #clinicalresearch

A new meta-analysis comparing iv vs pn dexamethasone for the intescalene brachial plexus block [https://lnkd.in/e6_zqdfs]. In brief, there is low-quality evidence that perineural administration of dexamethasone as a local anaesthetic adjunct increases duration of analgesia by an average of 2 h compared with intravenous injection for interscalene brachial plexus block. Given the limited clinical relevance of this difference, the off-label use of perineural administration, and the risk of drug crystallisation, we recommend intravenous dexamethasone administration.

🔹Review article: “#Neuraxial drug delivery in #painmanagement: An overview of past, present & future“ by Tony Yaksh et al. in Best Pract Res Clin Anaesthesiol (IF 4.7) (2023) 👉🏼 https://lnkd.in/dqcQYivS 🔹Mechanisms of spinal pain processing - the role of afferent terminals, #dorsalrootganglion (#DRG) & #dorsalhorn 🔹Regulation of neuraxial sensory processing - the role of #opiates, N-type calcium channels, NMDA receptors, voltage-gated sodium channels & toll-like receptor 4 🔹Current advances - therapeutic platforms, #targetedtoxins, genome targeting motifs 🔹Neuraxial delivery - pericatheter distribution & enhanced rostrocaudal spread (the role of microboluses & high-exit resistant catheter valves) 🔹#Intrathecal drug safety - local anesthetics, #morphine masses (#Granulomas; #keloidscars) 🔹My favorite: Fig. 8: asymmetric distribution of solute after a lumbar intrathecal injection (at a low infusate concentration the local concentrations are adequate over a narrow rostro caudal extent, around the injection site but when given in the same column but at a higher concentration, the range over which the hypothesized target concentrations are achieved is considerably broader!) #TDD #IDDS #neuromodulation #neurosciences #chronicpain #cancerpain #pumpentherapie #schmerzpumpe #rückenschmerzen #intrathekal #CRPS #tumorschmerzen #chronischeschmerzen #UniklinikKöln #ενδορραχιαίαέγχυσηφαρμάκων #χρόνιοςπόνος #καρκινικόςπόνος #νευροτροποποίηση #Nöromodülasyon #kronikağrı #morfinpompası #tümörağrısı #baklofenpompası

The first European biosimilar to Stelara, ustekinumab, has been approved. In 2024, this marks a significant milestone in the development of biosimilars and the expansion of treatment options for patients. 🌍 Join me for a deep dive into the world of biosimilars, as we explore the scientific and regulatory intricacies of developing high-quality, safe, and effective alternatives. Through symmetric training on quality and regulatory requirements, we aim to promote best practices and ensure patient safety.#BiosimilarDevelopment #UstekinumabBiosimilar #Stelara #BiopharmaIndustry #HealthcareInnovation #PatientAccess #RegulatoryLandscape #HealthcareCosts #symmetrictraining

Potentially lost in some of the big gastroenterology data releases at DDW last week were the announced phase 2 findings for etrasimod (known as Velsipity in ulcerative colitis) in eosinophilic esophagitis (EoE). The data show etrasimod efficacy in terms of eosinophil reduction (primary endpoint), but also in terms of symptom improvement (Dysphagia Symptom Questionnaire scores). While a potential launch is still a while away, strong performance on both those measures, plus the oral formulation should help etrasimod have success in this market. Etrasimod will try to model the successful launch that Dupixent has had in EoE, but differentiate based on oral vs. injectable formulation. #gastroenterology #clinicaldata https://lnkd.in/ePUKcavH

The Feb 8 issue of #NEJM just landed in my mailbox. I wrote the editorial "Psoriasis - More Progress but more questions" I discuss the latest stunning advance, Johnson & Johnson's phase 2 trial of an ORAL IL-23 receptor antagonist PEPTIDE for #psoriasis. I make the following points: 1. JNJ-77242113 achieved #PASI90 in 60% of patients - similar to some of our best biologics but in a pill! 2. General well tolerated but two #infections (SAEs COVID and an infected cyst) + and one suicide attempt need to be further evaluated in larger trials 3. #Obesity appeared to impact efficacy and having to take it twice a day on an empty stomach may diminish efficacy in real world settings 4. The progress made in developing drugs that clear psoriasis is tempered by a relative lack of progress in understanding the effect of the treatments on preventing #psoriaticarthritis #diabetes & #cardiovasculardisease To further advance the science and management of psoriasis the next generation of trials will need to have a #pragmatic, randomized design, active comparators, larger sample sizes and longer durations to determine which treatments, if any, restore not only the skin to normal but also the patient's overall health and lifespan. Only then will the full promise of these advances be realized.

Trust the unique formulation of IN.PACT™ for precise drug delivery, ensuring a sustained anti-restenotic effect¹. See the difference in the results. https://bit.ly/3S7JfEu

A Comparative Study of Osteoporosis Treatments Adherence and Cost-Effectiveness A study examined the use of alendronate and its alternatives in osteoporosis treatment. Patients and healthcare providers preferred intravenous zoledronate due to its simplicity and high adherence rates. However, oral bisphosphonates were found to be more cost-effective. The study emphasizes the importance of involving stakeholders in research to address real-world needs and improve healthcare strategies. Continued research is needed to optimize treatment outcomes and cost-effectiveness. For more details please click the link! https://lnkd.in/dfAiqi9p #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical